Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
Conditions
Interventions
- DRUG: Doravirine, Tenofovir, Lamivudine
- DRUG: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
- DRUG: Baseline regimen of cobicistat-boosted elvitegravir
- DRUG: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
- DRUG: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Sponsor
Merck Sharp & Dohme LLC